Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.
about
PEGylated Adenoviruses: From Mice to MonkeysCircumventing antivector immunity: potential use of nonhuman adenoviral vectorsA recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapyEvaluation of biodistribution and safety of adenovirus vector containing MDR1 in miceAdenovirus encoding human platelet-derived growth factor-B delivered to alveolar bone defects exhibits safety and biodistribution profiles favorable for clinical use.A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.miR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activityEvaluation of adenovirus vectors containing serotype 35 fibers for vaccinationTruncated active human matrix metalloproteinase-8 delivered by a chimeric adenovirus-hepatitis B virus vector ameliorates rat liver cirrhosis.Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity.Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapyA new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses.Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus)INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.Fiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivoAdenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.Intracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responsesT-cell immunity generated by recombinant adenovirus vaccines.Novel vectors for in vivo gene delivery to vascular tissue.Gene therapy of gynaecological diseases.Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model.TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectorsSelective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3.CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.EMMPRIN reduction via scFv-M6-1B9 intrabody affects α3β1-integrin and MCT1 functions and results in suppression of progressive phenotype in the colorectal cancer cell line Caco-2.Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatmentFiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma.Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.In Vivo Hematopoietic Stem Cell Transduction.Rescue of chimeric adenoviral vectors to expand the serotype repertoire.A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells.Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.Biodistribution studies: understanding international expectations.
P2860
Q24635276-46434E10-6C4C-439E-BC16-85141716F785Q26995655-14145257-67C1-4795-AE38-2290D7610C96Q30959165-688D5C7F-5E29-4CD6-A1CD-0A626C0CFFAFQ33640779-9F93B385-E0E8-43D7-A6A7-E9BD1D55FF0EQ33688505-23E9B549-B126-4CB6-B95A-42A8C6135525Q34369139-A8AFE230-429D-4D3B-A4EC-1CCA16ADA80EQ34422828-794DA1E2-9B60-422C-9C66-D239C1DA6C08Q34507185-E5831C10-FDDB-413E-96F8-723F5DB44844Q34542461-9C33A202-BA6F-4042-B47F-8FA0C61675B0Q34717992-1A6496A8-6404-4271-B891-4CF9D60EB6C7Q35139196-DA4350E7-FF16-4746-A8C0-863A1F24768DQ35569426-4FC4720D-51C9-48D3-929B-FD89ABF3673EQ36023115-E1725EC4-CD37-4DD1-B643-6B66292C06E2Q36055718-6E644441-BB35-44A6-84D0-9B1E8ED8DA91Q36209205-5B196143-F02C-437C-AA17-13BA78544AF3Q36315434-9A81BC38-5C94-4203-80AF-ECF8E3D9BB62Q36535456-9FC063D0-B0FC-4891-892E-6833F3C9153CQ36539060-B173CAF0-A758-4FB6-9C17-AFE9BA61DDB8Q36628042-2488B5EB-711A-4418-90C5-0B2805F8EBA2Q36837129-F28AA53E-DC72-4F37-B0CF-1E69EA854669Q36842711-819D617A-DF1A-4C8E-B9AE-341659A384C8Q36922247-AC462274-40F7-475B-BF25-B98F64E36D78Q37227135-6605346C-0D47-4A22-A739-EDCEA36D876FQ37309252-6D63B35D-4F3A-499D-AE3C-FA8BD5139055Q37322648-8A1F0076-550B-4206-BFF6-2F6B39A0207FQ37394036-4F8D4712-07DF-4A8B-85CE-615E48FC9945Q37404870-51D9DAA1-747B-4A3B-809A-4DBB51CA21C4Q37718861-B36EACEB-CD3E-406C-B247-DCC705E5C440Q38614156-F9266621-CE3E-4D11-8BAA-800F8D5D9554Q38985433-47100EF8-5AFB-4BA7-A8BF-A93FFEF6EB65Q39142095-DEFD306B-0122-4C06-BD7C-2D952B8042C6Q39278465-1D76BDCB-51AB-4E77-B849-A2A5AF675305Q39889523-0DD0A058-5886-4C39-895E-73DE34D0533CQ40012391-368145D7-EF79-4B32-B8D0-C270F6FAC752Q40045829-415D50B2-6A27-4195-8FCC-BCD83ABD810DQ40188439-04437427-8C5D-4DA8-A17B-3FDF334C91BCQ40223632-2EF13369-BFA5-4723-AF16-0F4D52CDC181Q40250421-C70FF38B-13BB-4EE5-838C-C6A338963DBFQ40327515-DECBD528-F98F-4EDF-BCBD-04501ECC8ED5Q45756302-2930C6C4-9CB0-4FB4-93C7-473B1757DA95
P2860
Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Evaluation of biodistribution ...... venous injection into baboons.
@ast
Evaluation of biodistribution ...... venous injection into baboons.
@en
Evaluation of biodistribution ...... venous injection into baboons.
@nl
type
label
Evaluation of biodistribution ...... venous injection into baboons.
@ast
Evaluation of biodistribution ...... venous injection into baboons.
@en
Evaluation of biodistribution ...... venous injection into baboons.
@nl
prefLabel
Evaluation of biodistribution ...... venous injection into baboons.
@ast
Evaluation of biodistribution ...... venous injection into baboons.
@en
Evaluation of biodistribution ...... venous injection into baboons.
@nl
P2093
P2860
P356
P1433
P1476
Evaluation of biodistribution ...... avenous injection into baboons
@en
P2093
André Lieber
Anuj Gaggar
Hans-Peter Kiem
Shaoheng Ni
Zong-Yi Li
P2860
P304
P356
10.1089/HUM.2005.16.664
P577
2005-06-01T00:00:00Z